MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

AstraZeneca plc Company Profile (LON:AZN)

Consensus Ratings for AstraZeneca plc (LON:AZN) (?)
Ratings Breakdown: 5 Sell Rating(s), 14 Hold Rating(s), 11 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Hold (Score: 2.26)
Consensus Price Target: GBX 4,690.98

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
Show:
DateFirmActionRatingPrice TargetActions
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2016Societe GeneraleReiterated RatingBuyGBX 6,900View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2016Deutsche BankReiterated RatingBuyGBX 5,600View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016Shore CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016HSBCReiterated RatingHoldGBX 4,240View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/15/2016BNP ParibasReiterated RatingOutperformGBX 5,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/14/2016Jefferies GroupBoost Price TargetHoldGBX 3,900 -> GBX 4,100View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2016Berenberg BankReiterated RatingBuyGBX 4,950View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/7/2016JPMorgan Chase & Co.Set Price TargetNeutralGBX 3,900View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Beaufort SecuritiesReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Goldman SachsSet Price TargetSellGBX 3,700View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/17/2016Credit SuisseReiterated RatingUnderperformGBX 4,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016Sanford C. BernsteinSet Price TargetNeutralGBX 4,352View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/25/2016BarclaysReiterated RatingEqual WeightGBX 5,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2016Liberum CapitalReiterated RatingBuyGBX 5,300View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016NatixisReiterated RatingNeutralGBX 4,456View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2016NomuraLower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016Bryan, Garnier & CoReiterated RatingBuyGBX 5,520View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016Morgan StanleyLower Price TargetOverweightGBX 5,300 -> GBX 5,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015Kepler Capital MarketsReiterated RatingReduceGBX 3,700View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2015DanskeUpgradeHoldGBX 4,400View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/9/2015Redburn PartnersUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Cenkos Securities LtdReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for AstraZeneca plc (LON:AZN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for AstraZeneca plc (LON:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)
Insider Trading History for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807Tweet This Trade  Share This Trade on StockTwits
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480Tweet This Trade  Share This Trade on StockTwits
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700Tweet This Trade  Share This Trade on StockTwits
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005Tweet This Trade  Share This Trade on StockTwits
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705Tweet This Trade  Share This Trade on StockTwits
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666Tweet This Trade  Share This Trade on StockTwits
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for AstraZeneca plc (LON:AZN)
DateHeadline
06/24/16 07:02 AM[$$] Few bright spots in UK traders' sea of red - [at Financial Times] - As a sea of red swept across City traders' screens on Friday, investors took refuge in the few stocks with sufficient exposure to overseas currencies or gold to be able to ride out the Brexit financial ...
06/17/16 10:36 AMAstraZeneca PLC (NYSE:AZN) To FDA: No More Crestor Generics Until 2023
06/17/16 10:36 AMAstraZeneca PLC (LON:AZN) price target maintained to GBX4,240 as issued in a report today by HSBC
06/15/16 12:17 PM[$$] Brexit conspicuous by its absence in UK groups' annual reports - [at Financial Times] - Whatever the outcome of next week's vote in the UK on its EU membership, the country's companies face their biggest political risk of the past 50 years or more. Yet they are very bad at reporting on it, ...
06/14/16 07:52 AMAnalyst's Checklist Stocks: Skyline Medical Inc. (NASDAQ:SKLN) , Astrazeneca PLC (NYSE:AZN) - Street Updates
06/14/16 05:35 AMWill Shire plc and AstraZeneca plc protect your portfolio from the upcoming storm? -
06/13/16 10:44 AMWorthy Stock Update: AstraZeneca PLC (NYSE:AZN) - News Oracle
06/13/16 10:44 AMPrice Target Summary: CenturyLink, Inc. (NYSE:CTL), AstraZeneca PLC (NYSE:AZN) - Beacon Chronicle
06/09/16 02:45 PMPut Volume Skyrockets as AstraZeneca plc (AZN) Slides - Schaeffers Research (blog)
06/06/16 11:01 AMEarnings in Focus: Wynn Resorts Ltd. (NASDAQ:WYNN), AstraZeneca PLC (NYSE:AZN) - Beacon Chronicle
06/06/16 11:01 AMAnalyst Buzz: AstraZeneca PLC (NYSE:AZN) - News Oracle
06/06/16 08:07 AMAstraZeneca’s Key Focus: Oncology -
05/31/16 03:00 AMWill AstraZeneca plc, Shire plc and Smith & Nephew plc help you survive Brexit? -
05/30/16 06:30 AMRelypsa Up on CRL for AstraZeneca Hyperkalemia Drug -
05/29/16 07:23 AMOddo Securities Reiterates Buy Rating for AstraZeneca plc (AZN) - Let Me Know About This - Oddo Securities Reiterates Buy Rating for AstraZeneca plc (AZN)Let Me Know About ThisAstraZeneca plc logo AstraZeneca plc (LON:AZN)'s stock had its “buy” rating restated by equities research analysts at Oddo Securities in a note issued to investors on Tuesday. They presently have a GBX 5,400 ($78.14) price objective on the ...and more »
05/27/16 09:55 PMNotable Analysts Recommendation to Monitor: Astrazeneca PLC (NYSE:AZN) , Allergan plc. (NYSE:AGN) - Street Updates - InvestCorrectlyNotable Analysts Recommendation to Monitor: Astrazeneca PLC (NYSE:AZN) , Allergan plc. (NYSE:AGN)Street UpdatesOn 5/26/2016, shares of Astrazeneca PLC (NYSE:AZN) fell -0.10% in trading session and finally closed at $29.95. The company most recent volume stood at 5.48 million shares as compared to average volume of 4.13 million shares. Over the one year trading ...Trader's Healthcare Focused Stocks: Astrazeneca PLC (NYSE:AZN) , Mallinckrodt plc (NYSE:MNK)Is storiesAstrazeneca PLC (NYSE:AZN) Analyst ReviewRisers & FallersAstrazeneca Plc (NYSE:AZN) Sellers Increased By 12.71% Their ShortsWall Street Hints and NewsThe Post -Sonoran Weekly Review -InvestCorrectlyall 10 news articles »
05/27/16 09:53 AM[$$] Denys Henderson, industrialist who split up ICI, 1932-2016 - [at Financial Times] - Sir Denys Henderson, who has died aged 83, was the Imperial Chemical Industries chairman who transformed an old British empire institution into two modern companies. The 1993 demerger into a commodity ...
05/27/16 07:25 AMTrader's Healthcare Focused Stocks: Astrazeneca PLC (NYSE:AZN) , Mallinckrodt plc (NYSE:MNK) - Is stories - Trader's Healthcare Focused Stocks: Astrazeneca PLC (NYSE:AZN) , Mallinckrodt plc (NYSE:MNK)Is storiesAstrazeneca PLC (NYSE:AZN) decreased -0.10% to $29.95 while traded 5.48 million shares on 5/26/2016. The stock price negotiated for value between $29.67 to $30.08 in recent trading session. During the past 52 weeks, the stock's price witnessed a ...Notable Analysts Recommendation to Monitor: Astrazeneca PLC (NYSE:AZN) , Allergan plc. (NYSE:AGN)Street UpdatesAstrazeneca PLC (NYSE:AZN) Analyst ReviewRisers & FallersAstraZeneca (LON:AZN) Broker RoundupShare Trading Newsall 7 news articles »
05/27/16 07:06 AMAstraZeneca plc (4.71%), Centrica plc (5.87%) and United Utilities Group plc (3.97%) are dividend WINNERS! -
05/27/16 04:54 AMRelypsa Scores Big Win When Pharma Rival Flops at FDA -
05/27/16 04:11 AMAstraZeneca potassium drug delayed by manufacturing snag -
05/26/16 06:15 PMETF’s with exposure to AstraZeneca Plc : May 26, 2016 -
05/26/16 07:41 AMRelypsa Inc: Brace for FDA Decision on AstraZeneca’s ZS-9 - The Food and Drug Administration is scheduled to decide on AstraZeneca plc's (ADR) (NYSE:AZN) new drug application seeking approval for its recently acquired hyperkalemia drug, ZS-9, on Thursday. The decision will have a large impact on rival drugmaker ...
05/26/16 07:41 AMAstraZeneca plc (NYSE:AZN) Received Positive Phase 3 Data Amidst Stiffening Competition With GlaxoSmithKline plc (NYSE:GSK) - AstraZeneca plc (NYSE:AZN) announced that it has received positive phase 3 results on benralizumab, its candidate for severe asthma. AstraZeneca announced that the drug had performed better than placebo at paring down annual asthma exacerbation rate in ...
05/26/16 03:37 AMAstraZeneca Plc breached its 50 day moving average in a Bullish Manner : AZN-GB : May 26, 2016 -
05/25/16 04:22 PMPreview of Analysts Recommendation: XenoPort, Inc. (NASDAQ:XNPT) , Astrazeneca PLC (NYSE:AZN) - Street Updates - Street UpdatesPreview of Analysts Recommendation: XenoPort, Inc. (NASDAQ:XNPT) , Astrazeneca PLC (NYSE:AZN)Street UpdatesOn 5/24/2016, XenoPort, Inc. (NASDAQ:XNPT) ended trading session higher at $6.99 with +1.60%. The company traded a volume of 10.21 million shares as comparison to average volume of 1.47 million shares. During the 52 –week period, the stock's price ...and more »
05/25/16 07:34 AMAstraZeneca plc (NYSE:AZN) Received Positive Phase 3 Data Amidst Stiffening Competition With GlaxoSmithKline plc ... - Market Exclusive - Market ExclusiveAstraZeneca plc (NYSE:AZN) Received Positive Phase 3 Data Amidst Stiffening Competition With GlaxoSmithKline plc ...Market ExclusiveAstraZeneca plc (NYSE:AZN) announced that it has received positive phase 3 results on benralizumab, its candidate for severe asthma. AstraZeneca announced that the drug had performed better than placebo at paring down annual asthma exacerbation ...Where AstraZeneca plc (ADR) (NYSE:AZN) Stands on Analytical Review Chart?The Point ReviewWhat analysts believe about this Healthcare Stock? AstraZeneca plc (AZN)News OracleAstrazeneca Plc (NYSE:AZN) Shorted Shares Increased By 15.51%Franklin IndependentRealistInvestor.com -CCH Daily Newsall 6 news articles »
05/24/16 08:03 AMAnalyst's Noticeable Buzzers: Exelixis, Inc. (NASDAQ:EXEL) , Astrazeneca PLC (NYSE:AZN) - Street Updates - Analyst's Noticeable Buzzers: Exelixis, Inc. (NASDAQ:EXEL) , Astrazeneca PLC (NYSE:AZN)Street UpdatesExelixis, Inc. (NASDAQ:EXEL) accumulated +7.91%, closing at $6.00 after floating between $5.70 and $6.14. The company has market capitalization of $1.37B. It has twelve month low of $3.08 and twelve month high of $6.81. The recent traded volume of ...and more »
05/24/16 07:31 AMWhy AstraZeneca plc and Shire plc are 2 growth stars -
05/24/16 05:37 AMAstraZeneca plc may never recover, is it time to buy Hikma Pharmaceuticals plc? -
05/23/16 04:27 PMWhat analysts believe about this Healthcare Stock? AstraZeneca plc (AZN) - News Oracle - What analysts believe about this Healthcare Stock? AstraZeneca plc (AZN)News OracleThe Company gained 1.07% and finished at $28.68. The daily volume was measured at 3.63 million shares. The 52-week high of the share price is $34.88 and the 52-week low is $27.68. The company has a market cap of $72.71 Billion. The stock has a P/E ...
05/23/16 09:14 AMWhere AstraZeneca plc (ADR) (NYSE:AZN) Stands on Analytical Review Chart? - The Point Review - The Point ReviewWhere AstraZeneca plc (ADR) (NYSE:AZN) Stands on Analytical Review Chart?The Point ReviewAstraZeneca plc (ADR) (NYSE:AZN) has grabbed the attention from analysts, when it saw a value increase of 1.09 percent in the last trading session. A total of 3.64 million shares exchanged hands during the intra-day trade compared with its average ...
05/23/16 08:45 AMFDA staff question utility of Sanofi diabetes drugs - [Reuters] - A preliminary review by the U.S. Food and Drug Administration questioned whether Sanofi SA's experimental diabetes drug lixisenatide contributed any benefit to a fixed-dose combination product the company hopes to market. The review comes ahead of a May 25 meeting of an FDA advisory panel that will discuss lixisenatide and a separate treatment, iGlarLixi, which delivers lixisenatide and Sanofi's drug Lantus, known also as insulin glargine, in a fixed dose combination. The FDA is not obliged to follow the recommendation of its advisory panels but typically does so.
05/23/16 02:40 AMAre AstraZeneca plc, Eco Animal Health Group plc and Advanced Medical Solutions Group plc the top healthcare picks right now? -
05/21/16 04:07 PMAstraZeneca plc (NYSE:AZN) &Immunomedics, Inc.(NASDAQ:IMMU)Healthcare Stock's Buzzers - Wall Street 24 - AstraZeneca plc (NYSE:AZN) &Immunomedics, Inc.(NASDAQ:IMMU)Healthcare Stock's BuzzersWall Street 24On Thursday, Shares of AstraZeneca plc (ADR) (NYSE:AZN)lost-1.63% to $28.38. The share price is trading in a range of $28.11 – $28.50. The stock exchanged hands with 2.99 Million shares contrast to its average daily volume of 3.62 Million shares.and more »
05/20/16 07:52 AMDeutsche Bank retained AstraZeneca PLC (LON:AZN) as 'Buy' With 5600 PT - FTSE News - FTSE NewsDeutsche Bank retained AstraZeneca PLC (LON:AZN) as 'Buy' With 5600 PTFTSE NewsAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, ...Deutsche Bank Reiterates Buy Rating for AstraZeneca PLC (LON:AZN) StockWall Street Hints and Newsall 35 news articles »
05/20/16 06:22 AMChina slashes GSK, AstraZeneca drug prices in cost-cutting drive - [Reuters - UK Focus] - SHANGHAI/LONDON, May 20 (Reuters) - Chinese health authorities announced price cuts of up to two-thirds for three expensive drugs on Friday in the latest move to reduce the cost of healthcare for patients in the world's second-biggest economy. The National Health and Family Planning Commission said the cost of GlaxoSmithKline (Other OTC: GLAXF - news) 's hepatitis B drug Viread would fall to 490 yuan ($75) a month from 1,500, while AstraZeneca (NYSE: AZN - news) 's lung cancer pill Iressa falls to 7,000 from 15,000. Icotinib, another lung cancer drug made by China's Betta Pharmaceuticals, will come down to 5,500 from 12,000 yuan a month.
05/19/16 09:35 PMCambiar Investors LLC Increased Astrazeneca Plc (NYSE:AZN) by $200.69 Million as Shares Declined - CCH Daily News - Cambiar Investors LLC Increased Astrazeneca Plc (NYSE:AZN) by $200.69 Million as Shares DeclinedCCH Daily NewsCambiar Investors Llc increased its stake in Astrazeneca Plc (NYSE:AZN) by 4778.33% based on its latest 2016Q1 regulatory filing with the SEC. Cambiar Investors Llc bought 7.17M shares as the company's stock declined 15.69% while stock markets rallied.and more »
05/19/16 04:27 PMOverview of Analysts Suggestions: MannKind Corporation (NASDAQ:MNKD) , Astrazeneca PLC (NYSE:AZN) - Street Updates - Overview of Analysts Suggestions: MannKind Corporation (NASDAQ:MNKD) , Astrazeneca PLC (NYSE:AZN)Street UpdatesAstrazeneca PLC (NYSE:AZN) moved in green zone with rise of +0.06 points or +0.21% to $28.85. The company has a market worth of $72.99B.Total 3.81 million shares were exchanged in last trading session as opposed to average volume of 4.11 million ...and more »
05/19/16 05:30 AMAstraZeneca plc goes ‘nuclear’ on R&D spend to double sales -
05/18/16 09:31 PMAstraZeneca drug fails gastric cancer trial - AstraZeneca PLC (LON:AZN, NYSE:AZN) says its Lynparza cancer drug has failed a detailed test for fighting advanced gastric cancer. Lynparza used in conjunction with paclitaxel chemotherapy did not meet the “primary endpoint” of overall survival in the ...
05/18/16 09:31 PMAstraZeneca plc (ADR) Falls as Lynparza Fails in Gastric Cancer Trial - ... across a range of cancers as the setback is not expected to affect the results of other clinical studies AstraZeneca Plc (ADR) (NYSE:AZN) faces a major setback after its ovarian cancer drug, Lynparza failed in late stage clinical study testing the ...
05/18/16 09:31 PMAstraZeneca plc (NYSE:AZN) Begins $1.1B Cost-Cutting Plan With Sales Reps Cutbacks - AstraZeneca plc (NYSE:AZN) confirmed earlier this week the cutting of its Publicis Touchpoint Solutions contract. The company is also reviewing its list of direct employees. This cutback plan is part of AstraZeneca’s proposals to cut its annual costs by ...
05/18/16 04:24 PMCan AstraZeneca plc (AZN) New Drugs Replace Near-To-Expire Crestor? - Business Finance News - Business Finance NewsCan AstraZeneca plc (AZN) New Drugs Replace Near-To-Expire Crestor?Business Finance NewsAstraZeneca plc (ADR) (NYSE:AZN) is working on multiple investigational molecules for the treatment of rare and life-threatening diseases. In pursuit of research and development (R&D), the drugmaker has announced comprehensive positive clinical study ...AstraZeneca plc (ADR) (NYSE:AZN) Posts Positive Phase III Trial Results For $2 Billion Asthma DrugMarket ExclusiveActive Stocks on Frontline- AstraZeneca PLC (NYSE:AZN), Suncor Energy (NYSE:SU), F5 Networks (NASDAQ:FFIV)Seneca GlobeAstraZeneca's Severe Asthma Drug Positive in Phase IIIYahoo NewsMarketWatch -Nasdaq -Wall Street Journalall 41 news articles »
05/18/16 08:24 AMAstraZeneca's Severe Asthma Drug Positive in Phase III -
05/18/16 07:50 AM4 Stunning 5%+ Yielders! AstraZeneca plc, TUI AG, Marston’s plc and Taylor Wimpey plc -
05/18/16 04:00 AMWhy is Neil Woodford so bullish on drugmakers GlaxoSmithKline plc, AstraZeneca plc and 4D Pharma plc? -
05/18/16 01:44 AMInsight - Pascal Soriot's big experiment: reinventing AstraZeneca -
05/18/16 01:36 AMAstraZeneca's Lynparza fails in gastric cancer combination test -
05/18/16 01:25 AMAstraZeneca’s Lynparza Doesn’t Improve Gastric Cancer Survival -
About AstraZeneca plc

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $57.25
  • 50 Day Moving Average: $3925.72
  • 200 Day Moving Average: $4122.70
  • P/E Ratio: 17.53
  • P/E Growth: 7.47
  • Market Cap: $51.00B
  • Current Quarter EPS Consensus Estimate: $3.97 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha